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Epstein–Barr virus (EBV)-encoded latent membrane protein 1 (LMP1) is required for viral transformation and has been
shown to protect lymphocytes from apoptosis. However, the effect of LMP1 on cells of epithelial origin remains poorly
understood. Using the epithelial cell line HeLa in which the expression of LMP1 is inducibly regulated by tetracycline, we
demonstrate that apoptosis triggered by ligation of the death receptor, Fas, or by the chemotherapeutic agent, etoposide, is
potentiated by LMP1. Apoptosis was assessed by nuclear condensation and activation of caspase-3-like enzymes with
concomitant proteolysis of the nuclear caspase substrate, poly(ADP-ribose) polymerase. However, the effect of LMP1 in
HeLa cells appeared to be stimulus-dependent since apoptosis induced by tumor necrosis factor (TNF) was inhibited.
Moreover, we observed an upregulation of the zinc finger protein A20 and a decrease in expression of Bcl-2 upon induction
of LMP1 in HeLa cells. Taken together, these data further our understanding of the function of LMP1 in epithelial cells and
suggest that LMP1, similar to its mammalian homolog CD40, can exert opposing effects on cell survival depending on theKey Words: apoptosis; caspases; Epstein–Barr virus; Fas
INTRODUCTION
Epstein–Barr virus (EBV) latent membrane protein 1
(LMP1) is essential for transformation of primary B lym-
phocytes into indefinitely proliferating lymphoblastoid
cell lines (Kaye et al., 1993). LMP1 confers a survival
advantage to EBV-infected B cells by protecting these
cells from apoptosis, and this was shown to depend on
LMP1-induced upregulation of the anti-apoptotic protein
Bcl-2 (Henderson et al., 1991). LMP1 also inhibits p53-
triggered apoptosis of Burkitt lymphoma (BL) cells
through a similar upregulation of Bcl-2 (Okan et al., 1995).
Inhibition of apoptosis is generally perceived of as being
an important step in the development of cancer (for
review, see Hanahan and Weinberg, 2000). LMP1 there-
fore has the potential to contribute to pathogenesis of
EBV-associated malignancy through the promotion of
cell survival as well as cell growth, at least in B cells.
However, it has recently been shown that other EBV
antigen(s) than LMP1 may play a role in apoptotic inhi-
bition of cells harboring EBV (Wade and Allday, 2000).
Indeed, EBV-encoded BHRF1, an early lytic protein with
sequence homology to Bcl-2, has been shown to sup-
press apoptosis induced by diverse stimuli, including
DNA-damaging agents, serum depletion, and calcium
ionophore stimulation (Henderson et al., 1993; Tarodi et0042-6822/02 $35.00
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al., 1994). Taken together, these observations suggest
that the apoptosis-modulating activity of LMP1 is condi-
tional, perhaps depending on the cell type or mode of
apoptosis induction.
In addition to lymphocytes, EBV also infects epithelial
cells. A tight association with EBV has been seen in
undifferentiated forms of nasopharyngeal carcinoma
(NPC), and about two-thirds of the EBV-positive NPC also
express LMP1 (Hu et al., 1995), raising the possibility that
this viral protein may play a role in the promotion of
malignant growth in epithelia at certain anatomical sites.
However, there are few reports on the role of LMP1 in the
modulation of apoptosis in cells of epithelial origin. Pre-
vious studies showed that when expressed in the lung
cancer cell line H1299, LMP1 blocks p53-mediated apo-
ptosis through its induction of the zinc finger protein A20,
an anti-apoptotic molecule (Fries et al., 1996). On the
other hand, LMP1 has been reported to enhance tumor
necrosis factor (TNF)-mediated apoptosis in intestine
407 epithelial cells, despite the occurrence of A20 induc-
tion (Kawanishi, 2000). Whether LMP1 modulates epithe-
lial cell apoptosis instigated by other stimuli has not
been established.
LMP1 is known to functionally mimic CD40 signaling
in B cells (Busch and Bishop, 1999; Uchida et al., 1999).
The latter molecule is a member of the TNF receptor
(TNFR) family and is expressed on the surface of acti-nature of the apoptosis trigger. © 2002 Elsevier Science (USA)
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other cell types (for review, see Young et al., 1998).
Interestingly, the apoptosis-modulating properties of
CD40 have been shown to be opposing and to depend
on the nature of the apoptotic stimulus. Hence, ligation of
CD40 rescues Ramos-BL cells from calcium ionophore-
and antigen receptor-triggered apoptosis (An and Knox,
1996), yet potentiates Fas-mediated apoptosis of the
same cells, despite the upregulation of the anti-apoptotic
molecules Bcl-2 and Bcl-XL under these conditions (An et
al., 1997). LMP1 and CD40 have been shown to bind
several of the same TNFR-associated factors (TRAFs),
namely TRAF-2, -3, and -5 (Young et al., 1998), and this
interaction thus provides further evidence that LMP1-
mediated signaling can intersect the TNFR pathway. In
addition, the adaptor protein termed TNFR-associated
death domain protein (TRADD) has been reported to bind
LMP1 (Floettmann et al., 1998), but does not bind CD40
directly, indicating the possibility for differential signaling
mediated by these two molecules. Importantly, TNFR1
and the so-called death receptor known as Fas (APO-1/
CD95) have both been implicated in the physiological
regulation of apoptosis in cells of various origin, includ-
ing lymphocytes (for review, see Krammer, 2000). Fas
also recruits an adapter protein, designated Fas-associ-
ated death domain protein (FADD), upon binding of its
cognate ligand, and this results in the aggregation and
activation of upstream caspases, thus initiating a cas-
cade of proteolytic activity with subsequent cleavage of
cellular proteins and dismantling of the cell by apoptosis
(Krammer, 2000). In addition to death receptor-mediated
triggering of apoptosis, a number of death stimuli, includ-
ing DNA-damaging agents such as etoposide, elicit mi-
tochondrial perturbation with release of apoptogenic fac-
tors from these organelles and subsequent activation of
caspases, including caspase-3, resulting in the rapid
demise of the cell (for review, see Kroemer and Reed,
2000).
In the present study, we utilized a tetracycline-regu-
lated LMP1 expression system (Floettmann et al., 1996)
to obtain inducible LMP1 expression in the epithelial cell
line HeLa. Apoptosis of HeLa cells was triggered by
three different stimuli acting via death receptors or at the
mitochondrial level under conditions which LMP1 was
induced or uninduced, and assessed by the activation of
caspase-3-like enzymes and characteristic nuclear apo-
ptotic changes. We observed a stimulus dependence of
apoptosis modulation by the inducible LMP1 in HeLa
cells insofar as TNF-triggered apoptosis was attenuated
by LMP1, whereas Fas- and etoposide-triggered apopto-
sis was potentiated in the same cells. The implications of
these findings for EBV-associated malignancy, and the
possible mechanism(s) underlying the differential out-
come of apoptosis triggering in LMP1-expressing cells,
are discussed.
RESULTS
Establishment of a tetracycline-regulated LMP1
expression system in the epithelial cell line HeLa
HeLa cells were transfected with the tTA-containing
plasmid pJEF3 and selected by in vitro culture in the
presence of 500 g/ml hygromycin B. Outgrowing cells
presenting as visible colonies were transferred to culture
plates, and the clones were tested for tTA activity by
transient transfection with the tTA reporter plasmid
pUHC13–3, containing a luciferase gene downstream of
tTA responder. Clone Ht27 (Ht  HeLa tTA), selected out
of 31 clones, showed the lowest luciferase activity in the
presence of tetracycline (1 g/ml) and the highest activ-
ity in the absence of tetracycline (data not shown). This
clone was therefore chosen for the next round of trans-
fection involving a tTA responder plasmid containing
LMP1 cDNA. Outgrowing cells after selection with 2
mg/ml geneticin were divided and cultured in the pres-
ence or absence of tetracycline. Tetracycline-regulated
LMP1 expression was monitored by Western blotting
using antibodies specific for LMP1. As shown in Fig. 1A,
several clones exhibited regulatable LMP1 expression.
In addition to stable induction of LMP1 upon multiple
passages, the Ht27/8 clone also displayed marked NFB
activation, as determined by the conventional luciferase
assay (Fig. 1B), and this clone was therefore selected for
use in further experiments.
Etoposide-triggered apoptosis of HeLa cells and
concomitant activation of caspase-3-like enzymes is
enhanced by inducible LMP1
When HeLa cells were exposed to etoposide, a topo-
isomerase II poison known to elicit apoptosis in vitro,
blebbing, and later floating cells, indicative of apoptotic
cell death, were observed (data not shown). Cells ex-
posed to etoposide (20 g/ml) were also stained with the
nuclear dye Hoechst 33258, and the number of apoptotic
cells exhibiting fragmented nuclei were counted (Fig. 2).
The percentage of apoptotic cells was completely sup-
pressed when cells were cultured in the presence of the
pan-caspase inhibitor zVAD-fmk2 (10 M), indicating that
cell death in this model is caspase-dependent. To deter-
mine the effect of LMP1 on apoptosis, HeLa cells were
cultured in the presence or absence of tetracycline for
48 h after plating and then incubated in medium supple-
mented with etoposide (20 g/ml) in the continued pres-
ence or absence of tetracycline. The earliest signs of
blebbing were seen at 10 h after the initiation of culture,
2 Abbreviations: BHRF1, BamHI rightward reading frame 1; DEVD-
AMC, aspartate-glutamate-valine-aspartate-7-amino-4-methyl-cou-
marin; tTA, tetracycline transactivator; zVAD-fmk, benzyloxycarbonyl-
valine-alanine-aspartate- fluoromethylketone.
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and blebbing and floating cells continued to appear
during after 2–3 days of exposure to etoposide (Fig. 3A
and data not shown). Etoposide-triggered cells were also
collected at different time points and analyzed for acti-
vation of caspase-3-like enzymes using the fluorogenic
peptide substrate, DEVD-AMC (50 M) (Nicholson et al.,
1995). As shown in Fig. 3B, etoposide-induced caspase
activity was enhanced by the expression of LMP1. On the
other hand, caspase activation in the absence of etopo-
side in HeLa cells expressing or not expressing LMP1
was minimal (Fig. 3C). Importantly, the addition of the
competitive caspase-3 inhibitor DEVD-CHO (50 nM) to
the cell lysates completely abrogated DEVDase activity,
thus confirming the specificity of these lysates for the
caspase-3 substrate (Fig. 3D). As expected, etoposide-
induced DEVDase activity, and its potentiation by LMP1,
was blocked by zVAD-fmk (data not shown). Hence,
LMP1 potentiates etoposide-triggered apoptosis up-
stream of the activation of caspase-3-like enzymes.
Fas-triggered apoptosis of HeLa cells is enhanced by
inducible LMP1
Agonistic anti-Fas antibodies are frequently used to
mimic the effect of the endogenous Fas ligand. We found
that HeLa cells are sensitive to treatment with anti-Fas
antibodies (100 ng/ml), albeit to a lesser extent than to
etoposide, with pronounced blebbing of cells starting to
occur at 4–5 h after exposure (data not shown). LMP1-
mediated modulation of apoptosis in this model was
confirmed by assessment of Hoechst 33258 staining of
fragmented nuclei (Fig. 4A). Fas-triggered (100 ng/ml)
cells were also collected at the indicated time points and
monitored for AMC release in a continuous fluorometric
caspase assay as described above (Fig. 4B). Importantly,
Fas-triggered caspase-3-like activity was consistently
enhanced by the expression of LMP1. A nonspecific,
toxic effect of LMP1 can thus be excluded since caspase
activation is an indicator of apoptotic—as opposed to
necrotic—cell death (Samali et al., 1999). To control for
the inducibility of LMP1 upon Fas ligation, cells were
analyzed by Western blot at various time points after
exposure to anti-Fas antibodies. The EBV-positive B cell
line Raji was used as a positive control. As shown in Fig.
4C, the inducibility of LMP1 was indeed sustained upon
Fas triggering, although the level of expression of LMP1
was decreased at later time points, most likely as a
result of a loss of cells through detachment. Moreover,
while LMP1 was shown to induce Fas expression in
some cell types (Devergne et al., 1998), our flow cyto-
metric analysis of the surface expression of Fas in the
presence or absence of LMP1 appears to rule out such
effects in the present model (Fig. 4D). Taken together, the
current data demonstrate that inducible LMP1 potenti-
ates Fas-triggered apoptosis of HeLa cells.
TNF-induced apoptosis and caspase activation in
HeLa cells is inhibited by inducible LMP1
The TNFR triggers a signaling cascade similar but not
identical to the Fas-mediated pathway (see Introduction).
To test whether the effect of LMP1 was specific for Fas,
the effect of TNF on HeLa cells was examined. After 2 h
of exposure to TNF (5 ng/ml) and cycloheximide (CHX; 20
g/ml), a few blebbing cells were evident, and at 10 h
after exposure, a large number of blebbing and floating
cells started to accumulate (data not shown). Apoptosis
induced by TNF was confirmed by staining of cells with
Hoechst 33258, and typical fragmented nuclei were vis-
FIG. 1. Tetracycline-regulated expression of LMP1 in HeLa cells. (A)
Three HeLa clones derived from outgrowing cells after selection in
hygromycin and geneticin were cultured in the presence or absence of
tetracycline (1 g/ml) for 24 h. Cell lysates were then assessed by
Western blotting using antibodies specific for LMP1 (clone S-12). The
EBV-positive B cell line Raji is used as a positive control. Ht HeLa tTA
(tetracycline transactivator). (B) HeLa cells (clone Ht27/8) were cultured
in the presence or absence of tetracycline for the indicated time points,
and NFB activity was determined using the luciferase assay as de-
scribed under Materials and Methods. The activity registered in tetra-
cycline (tet)  samples is set at 1 arbitrary unit and the activity in tet
samples is presented as fold numbers of induction. Data shown are
mean  SD of three independent experiments.
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ible in cells upon TNFR1 ligation (Fig. 5A). Activation of
caspase-3-like enzymes was monitored as above using
the peptide substrate DEVD-AMC (50 M). Interestingly,
a marked inhibition by LMP1 of TNF-triggered caspase-
3-like enzymes was observed (Fig. 5B). Similarly, Western
blotting showed that processing of poly(ADP-ribose)
polymerase (PARP), a known substrate for caspase-3,
and the generation of the characteristic 85 kDa fragment,
was attenuated in the LMP1-expressing cells (Fig. 5C).
Fas-triggered Raji cells were used as a positive control.
Importantly, Western blotting of HeLa cells expressing or
not expressing LMP1 demonstrated that LMP1 did not
affect the level of expression of TNFR1 in these cells (Fig.
5D). These data thus show that inducible LMP1 attenu-
ates TNF-triggered apoptosis of HeLa cells, upstream of
caspase-3 activation.
Inducible LMP1 regulates the expression of A20 and
Bcl-2 in HeLa cells
The anti-apoptotic effect of LMP1 in certain cell types
has been demonstrated to correlate with an upregulation
of the zinc finger protein A20 (Fries et al., 1996). More-
over, an LMP1-induced upregulation of Bcl-2 has been
reported in B cells (Henderson et al., 1991), while LMP1
has no effect on Bcl-2 levels in the leukemic T cell line
Jurkat (Kawanishi, 1997a). Therefore, we investigated the
effect of LMP1 in HeLa cells on these apoptosis-regulating
molecules using antibodies specific for A20 and Bcl-2,
FIG. 2. Etoposide-triggered apoptosis of HeLa cells is caspase-dependent. Cells were incubated in the presence or absence of the pan-caspase
inhibitor, zVAD-fmk (10 M), prior to stimulation with etoposide (20 g/ml) for the indicated time points. Apoptosis was determined as the percentage
of cells exhibiting characteristic fragmented nuclei. Data shown are mean  SD of one out of three independent experiments.
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respectively. As seen in Fig. 6A, an induction of LMP1 and
a concomitant upregulation of A20 can be seen in HeLa
cells incubated for 48 h in the absence of tetracycline. On
the other hand, the level of Bcl-2 is markedly decreased
upon induction of LMP1 in these cells (Fig. 6B). Taken
together, these data suggest that LMP1 can exert selective,
cell lineage specific effects on the expression of the anti-
apoptotic molecules A20 and Bcl-2.
FIG. 3. Inducible LMP1 potentiates etoposide-triggered apoptosis in HeLa cells. (A) HeLa cells expressing or not expressing tetracycline-
regulatable LMP1 were cultured in the presence or absence of etoposide (20 g/ml) for 24 h prior to assessment of Hoechst 33258 staining under
a fluorescence microscope. Arrows indicate typical apoptotic cells with fragmented nuclei. Original magnification, 60. (B) HeLa cells incubated as
above were monitored for caspase-3-like activity using the fluorescent peptide substrate, DEVD-AMC (50 M). The maximum rate of AMC release
(pmol/min) was estimated by linear regression (r2  0.99). Data shown are mean  SD of three independent experiments. (C) Caspase-3-like activity
in Ht27/8 cells cultured in regular medium, i.e., in the absence of etoposide. Cells were cultured with or without tetracycline, and caspase-3-like
enzyme activity was measured as described above. Data shown are mean  SD derived from two independent experiments. (D) Real-time recording
of AMC release in lysates of HeLa cells stimulated for 24 h with 20 g/ml etoposide in the absence (open circles) or presence (solid circles) of the
competitive inhibitor of caspase-3-like enzymes, DEVD-CHO (50 nM). Each data point represents the mean value of determinations performed in
triplicate.
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FIG. 4. Inducible LMP1 potentiates Fas-triggered apoptosis in HeLa cells. (A) HeLa cells expressing or not expressing tetracycline-regulatable
LMP1 were cultured in the presence or absence of agonistic anti-Fas antibodies (100 ng/ml) and then assessed for fragmented nuclei using the
Hoechst 33258 dye. Typical fragmented nuclei are indicated with arrows. Original magnification, 60. (B) HeLa cells were incubated as above for the
indicated time points and caspase-3-like activity was monitored by the in vitro cleavage of the fluorescent substrate DEVD-AMC (50 M). Data shown
are mean  SD of three independent experiments. (C) HeLa cells cultured in the presence or absence of tetracycline (tet; 1 g/ml) and then
coincubated with agonistic anti-Fas antibodies (100 ng/ml) for the indicated time points were assessed for LMP1 expression by Western blotting. The
EBV-positive B cell line Raji was used as a positive control. (D) Flow cytometric analysis of Fas surface expression in HeLa cells cultured with or
without tetracycline for 24 h. The leukemic T cell line Jurkat was used as a positive control. The solid line depicts staining with the anti-Fas mAb; the
dotted line depicts secondary antibody alone. Data are representative for three independent experiments.
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DISCUSSION
LMP1 has been reported to modulate lymphocyte ap-
optosis through its induction of the anti-apoptotic mole-
cules, Bcl-2 (Henderson et al., 1991) and A20 (Laherty et
al., 1992), and more recently through the upregulation of
the Bcl-2 homologues, Mcl-1 and Bfl-1 (Wang et al., 1996;
D’Souza et al., 2000). In the present study, apoptosis
mediated by TNFR1, but not by the related death receptor
Fas or the chemotherapeutic agent etoposide, was in-
hibited by tetracycline-regulated LMP1 in the epithelial
cell line HeLa. Moreover, the modulation of TNF-trig-
gered apoptosis correlated with an induction of A20 in
FIG. 5. Inducible LMP1 attenuates TNF-triggered apoptosis in HeLa cells. (A) Apoptosis was detected by Hoechst 33258 staining of LMP1-
expressing or nonexpressing HeLa cells exposed for 4 h to TNF (5 ng/ml) plus CHX (20 g/ml). A typical apoptotic cell is indicated with an arrow.
Original magnification,60. (B) Caspase-3-like activity was monitored in lysates of cells treated as above for the indicated time points. The maximum
rate of DEVD-AMC cleavage (pmol/min) was estimated by linear regression (r2 0.99). Data shown are mean SD of three independent experiments.
(C) HeLa cells (LMP1-expressing and nonexpressing) incubated in the presence or absence of TNF (5 ng/ml) for 4 h were assessed by Western
blotting using antibodies specific for PARP. Raji cells exposed to agonistic anti-Fas antibodies (100 ng/ml) for 8 h were used as a positive control.
The intact PARP molecule (116 kDa) and the characteristic caspase-mediated cleavage product (85 kDa) are indicated with arrows. (D) TNFR1
expression as determined by Western blot. Equal numbers of HeLa cells induced and uninduced for LMP1 expression were probed with anti-TNFR1
and anti-LMP1 antibodies, respectively. Raji cells were used as a positive control. Data shown in C and D are representative of at least three
independent experiments.
336 ZHANG ET AL.
these cells. Previous studies have shown that an en-
forced expression of A20 fails to diminish Fas-mediated
apoptosis (Ja¨a¨ttela¨ et al., 1996), and the fact that LMP1
yielded a potentiation of Fas-triggered apoptosis in HeLa
cells despite the upregulation of A20 is therefore not
surprising. Studies on the apoptosis-modulating function
of LMP1 in epithelial cells are scarce; nevertheless,
published observations suggest that LMP1, when ex-
pressed in epithelial cells, exhibits a uniform pattern of
inhibition or promotion of apoptosis in the same cell line
(Fries et al., 1996; Kawanishi, 2000). However, in the
model system used herein, its modulation is clearly stim-
ulus-dependent. The current observations are thus rem-
iniscent of those obtained in studies of the EBV-encoded
protein BHRF1, which also exerts an apoptosis-modulat-
ing effect which is stimulus- and cell type-dependent
(Foghsgaard and Ja¨a¨ttela¨, 1997). Furthermore, while
LMP1 expression in NPC cells has been shown to confer
growth enhancement, expression of LMP1 in gastric car-
cinoma cells resulted in enhanced apoptosis and hence
in growth suppression (Sheu et al., 1998), thus indicating
that the context of LMP1 expression is crucial for its
effect. An elevated A20 protein level may explain the
inhibition of TNF-induced apoptosis described herein, as
it has been reported that A20 selectively blocks the
pathways stimulated by certain apoptotic triggering
agents, notably TNF (Opipari et al., 1992; Ja¨a¨ttela¨ et al.,
1996). Another possible mechanism of apoptosis inhibi-
tion involves the molecular interaction of the intracellular
portion of LMP1. Two functional domains in the C-termi-
nal cytoplasmic tail of LMP1 associate with TNFR-asso-
ciated factors and the TNFR-associated death domain
protein, respectively, and mediate NFB activation (Izumi
et al., 1999 and references therein). The apoptosis-atten-
uating effect of LMP1 in cells exposed to TNF could thus
be explained by its possible competitive binding with
TRADD and subsequent attenuation of the cytotoxic sig-
nal mediated through TNFR1. However, it is also reason-
able to consider a role for NFB in the apoptosis mod-
ulation exerted by LMP1. Hence, we have observed a
potentiation of etoposide-induced caspase activation in
LMP1-expressing HeLa cells incubated in the presence
of a chemical NFB inhibitor (X. Zhong, L. Hu, B. Fadeel,
and I. Ernberg, unpublished data). Clearly, further studies
are needed to delineate the putative role of NFB, and of
TNFR-associated proteins, in the apoptosis signaling in
the current model.
Remarkably, while TNF-induced apoptosis is attenu-
ated by LMP1, our data show that caspase activation and
apoptosis of HeLa cells induced via the TNFR-related
death receptor, Fas, is enhanced. LMP1 thus differs from
the other EBV-encoded apoptosis-regulating protein
BHRF1, which was shown previously to protect epithelial
cells from apoptosis induced either through TNFR1 or
Fas stimulation (Kawanishi, 1997b). On the other hand,
Lu et al. (1996) reported the induction of apoptosis in the
epithelial cell line Rhek-1 by high levels of LMP1, an
effect that was most apparent under conditions of serum
starvation. Upregulation of Fas expression upon ligation
of CD40, the mammalian homolog of LMP1, has been
demonstrated (An et al., 1997) and these findings were
taken to account for the apoptosis-enhancing effect of
CD40. However, we failed to detect any consistent alter-
ations in surface expression of Fas upon LMP1 induction
in the present model. Apoptosis triggered by TNFR1 and
Fas shares many common features, such as the activa-
tion of “executioner” caspases, yet there are also differ-
ences which may account for the differential apoptosis-
modulating effect of LMP1. For instance, Fas signaling in
certain cell types involves mitochondrial amplification of
the original stimulus, with caspase-8-mediated cleavage
of the Bcl-2 family member Bid acting as a link between
the death receptor at the plasma membrane and mito-
chondria (Scaffidi et al., 1998; Yin et al., 1999). Impor-
tantly, etoposide-triggered apoptosis of HeLa cells is
also enhanced by LMP1, and our data indicate that LMP1
elicits its effect upstream of caspase-3 both in the Fas
and in the etoposide model. It is well established that
etoposide triggers apoptosis via mitochondrial perturba-
tion with subsequent activation of cytoplasmic caspases,
including caspase-3 (Sun et al., 1999), and depending on
the dose etoposide was shown to trigger the release of
FIG. 6. LMP1 regulates the expression of A20 and Bcl-2 in HeLa
cells. (A) HeLa cells (clone Ht27/8) were incubated in the presence or
absence of tetracycline (tet; 1 g/ml) for 48 h and cell lysates were then
monitored by Western blotting for the expression of LMP1 and A20
using specific antibodies. The EBV-positive B cell line Raji was in-
cluded as a positive control. Data are representative of four indepen-
dent experiments. (B) HeLa cells were incubated in the presence or
absence of tetracycline (1 g/ml) for 48 h and lysates were probed for
expression of LMP1 and Bcl-2, respectively. Raji cells were used as a
positive control. Data shown are representative of three independent
experiments.
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cytochrome c from the mitochondrial intermembrane
space through either a direct or an indirect mechanism
(Robertson et al., 2000). The potentiating effect of LMP1
on etoposide- and Fas-triggered apoptosis may thus
involve its interactions with factors upstream or at the
level of the mitochondrion, including members of the
Bcl-2 family, with subsequent potentiation of downstream
effector molecules such as caspase-3. Our observation
that Bcl-2 is downregulated by LMP1 in HeLa cells, and
the fact that overexpression of Bcl-2 in HeLa cells pro-
tects against both Fas- and etoposide-mediated apopto-
sis (Mandal et al., 1996; Asoh and Ohta, 1997; Yin and
Schimke, 1995; Lock and Stribinskiene, 1996), concurs
with this notion. Furthermore, Liu and associates (2002)
recently reported that Bcl-2 is significantly downregu-
lated by LMP1 expression in NPC cell lines, thus provid-
ing further evidence that the effect of LMP1 on Bcl-2
expression may be cell lineage specific.
Subversion of apoptotic control is a common phenom-
enon in the development of cancer. Viral proteins that are
required for survival in the host cell during the stages of
latency and lytic replication frequently target the apopto-
tic machinery of the cell and may thus contribute to
tumorigenesis (for review, see Hardwick, 1998; Thomson,
2001). LMP1 is such a viral factor which most likely
evolved to protect against untimely apoptosis during the
course of EBV infection of B cells, an important if not
exclusive reservoir of the latent virus. Based on the
well-established anti-apoptotic function of LMP1 in B
cells, it is reasonable to assume a similar function in
epithelial cells. However, as discussed above, the cur-
rent data show that the effect of LMP1 on epithelial cell
apoptosis depends critically on the nature of the stimu-
lus. LMP1 is consistently expressed in cancer in situ and
in premalignant lesions of the nasopharynx and is there-
fore a natural candidate protein to contribute to NPC
development (Pathmanathan et al., 1995). Nevertheless,
it is conceivable that a viral protein with multiple pheno-
typic properties may contribute differently to the initial
process of tumor development and the subsequent pro-
cess of tumor growth and progression. In this context,
the fact that the EBV genome frequently is lost after
long-term culture of established NPC cell lines indicates
that EBV infection may be more important in the early
development of NPC than for the maintenance of contin-
uous tumor growth. In addition, in trying to understand
the processes underlying tumor growth, one should con-
sider the extensive lymphoid infiltration evidenced in
NPCs, since such inflammatory cells may also contribute
death and survival signals, including CD40 ligand (Sbih-
Lammali et al., 1999), resulting in a complex in vivo
situation with multiple cell–cell and receptor–ligand in-
teractions.
Tumor sensitivity to radiation depends, at least in part,
on the proper functioning of the intrinsic apoptosis sig-
naling pathways of cancer cells (for review, see Zhivo-
tovsky et al., 1999). One may thus speculate that the high
sensitivity of NPCs to radiation, the first choice of treat-
ment of these tumors, may relate to the enhanced sen-
sitivity of LMP1-expressing HeLa cells to etoposide and
to Fas ligation. Indeed, the observation that LMP1 poten-
tiates apoptosis instigated by these stimuli is in line with
our previous observation that LMP1-positive NPCs have
a better prognosis than LMP1-negative tumors (Hu et al.,
1995). Interestingly, previous studies have demonstrated
that EBV-positive NPC specimens constitutively express
Fas (Sbih-Lammali et al., 1999). Moreover, Fas ligand
was recently shown to be upregulated in an EBV-positive
NPC cell line upon irradiation, and these data were taken
to suggest that Fas–Fas ligand interactions are involved
in the antitumor effect of ionizing radiation in these cells
(Abdulkarim et al., 2000). Furthermore, we recently ob-
served a negative correlation between Fas ligand and
LMP1 expression upon screening of a set of 50 NPC
biopsies (J-Y. Shao, I. Ernberg, P. Biberfeld, T. Heiden,
Q-L. Wu, Y-X. Zeng, and L-F. Hu, unpublished observa-
tions), which supports the notion of enhanced elimina-
tion of Fas ligand-expressing, LMP1-positive cells in
NPC. Clearly, further studies are needed to address the
putative role of LMP1 in radiation-induced apoptosis and
sensitivity of NPC to treatment.
In sum, the present studies demonstrate the effect of
LMP1 on apoptosis in cells of epithelial origin and serve
to underscore the marked stimulus-dependent effect of
this EBV-encoded apoptosis modulator. Elucidating the
function of LMP1 is important for the understanding of
the tumorigenic potential of EBV, and further studies in
cells of epithelial origin are warranted to unravel the
molecular mechanism(s) underlying the differential out-
come of LMP1 on epithelial cell apoptosis. It is hoped
that a better understanding of the signaling pathways
that control survival and death of epithelial cells will
allow treatment regimens to be optimized for EBV-asso-
ciated malignancies such as nasopharyngeal carci-
noma.
MATERIALS AND METHODS
Cell lines and plasmids
HeLa is a cell line derived from a human cervical
carcinoma. The cells were maintained in Iscove’s modi-
fied Dulbecco’s medium (Life Technologies), supple-
mented with 10% fetal calf serum (FCS), penicillin, and
streptomycin (Sigma). EBV-positive Raji B cells and leu-
kemic Jurkat T cells were maintained in RPMI 1640 me-
dium (Life Technologies) supplemented with 10% FCS
and antibiotics (Sigma). PJEF3 is a tTA responder con-
structed by inserting a hygromycin-resistance gene into
the plasmid pUHD15–1. pJEF6 is a plasmid containing
the LMP1 cDNA (Liebowitz et al., 1992) downstream of a
tTA responder. The two plasmids are described in Floett-
mann et al. (1996) and were the kind gift of Dr. Martin
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Rowe, Cardiff, U.K. pCon A B luc contains three B-
binding sites upstream of the luciferase gene.
LMP1 transfection
Two rounds of transfection were performed by coincu-
bating the cells with plasmid DNA mixed with 4 g/ml
lipofectin (Gibco). The transfected cells after the first
round were selected by 500 g/ml hygromycin B (Gibco)
as determined by cytotoxic titration. The tTA activity was
assessed by transiently transfecting the cells with the
plasmid pUHC13–3, containing the luciferase gene
downstream of a tTA responder. The clone with the
highest luciferase activity in the absence of tetracycline
and the lowest luciferase activity in the presence of
tetracycline was chosen for the second round of trans-
fection. After transfection with the pJEF6 plasmid and
selection with 2 mg/ml geneticin (Gibco), outgrowing
cells were tested for tetracycline-regulated LMP1 ex-
pression by Western blotting, using specific anti-LMP1
monoclonal antibodies (clone S-12). For determination of
NFB-driving luciferase activity, the pCon A kB luc plas-
mid was transfected as above. The cells were cultured
with or without tetracycline (1 g/ml) (Stratagene) or its
derivative doxycycline (1 g/ml) (Stratagene) before har-
vesting at the indicated time points. Ten microliters of
cell lysate was mixed with 50 l of the substrate luci-
ferrin (Promega) and immediately monitored with a
Turner design luminometer. The transfection efficiency
was normalized by assessment of -Gal activity ex-
pressed by the cotransfected plasmid. The relative light
units are calculated as the ratio of luciferase units and
OD420 values obtained in the -Gal assay.
Apoptosis triggering
The cells were plated in petri dishes and cultured in
complete medium supplemented with 1 g/ml tetracy-
cline for 48 h to remove basal LMP1 expression. Cells
were then cultured for another 24 h with or without
tetracycline. For apoptosis triggering, the medium was
supplemented with 5 ng/ml TNF (Pharmingen) plus 20
g/ml CHX (Sigma), 100 ng/ml anti-Fas antibody (Ig G1
isotype; Boehringer), or 20 g/ml etoposide (Sigma), and
incubated for the indicated time points. For some exper-
iments, the general caspase inhibitor, zVAD-fmk (10 M)
(Enzyme Systems Products), was added to cells 30 min
prior to coincubation with etoposide. Cells were subse-
quently harvested and processed for Western blotting,
assessment of caspase-3-like activity, or evaluation un-
der the fluorescence microscope, as described below.
Assessment of nuclear morphology
Cells were collected and stained with Hoechst 33258
(Sigma) to confirm the induction of apoptosis by classical
nuclear alterations (i.e., chromatin condensation). For
this purpose, cells were mounted on clean glass slides
by cytospin technique, fixed in acetone:methanol (1:1
v/v), and stained with Hoechst 33258 (10 g/ml) in the
dark for 10 min. The fluorescent nuclei were viewed
under a Nikon fluorescent microscope, and the percent-
age of fragmented nuclei present in at least 500 cells
was determined.
Caspase-3-like enzyme assay
Caspase-3-like activity was estimated in a continuous
fluorometric assay as previously described (Fadeel et al.,
1998). Briefly, cell lysates and substrate were combined
in a reaction buffer (100 mM HEPES, 10% sucrose, 5 mM
dithiothreitol (DTT), 106% NP-40, and 0.1% 3-[(3-cholami-
dopropyl) dimethylammonio] propane-1-sulphonic acid
(CHAPS), pH 7.25) and added in duplicate to a 96-well
plate. The cleavage of the fluorogenic peptide substrate
DEVD-AMC (50 M) (Peptide Institute, Inc., Osaka, Ja-
pan) was monitored by AMC liberation in a Fluoroskan II
plate reader (Labsystems, Stockholm, Sweden) using
355 nm excitation and 460 nm emission wavelengths.
Fluorescence was measured every 70 s during a 30 min
period and fluorescence units were converted to pico-
mole of AMC using a standard curve generated with free
AMC. Data from duplicate samples were then analyzed
by linear regression and are displayed as picomole AMC
release per min. For experiments conducted in the pres-
ence or absence of the specific inhibitor of caspase-3-
like enzymes, DEVD-CHO (50 nm), real-time recordings
of DEVDase activity (picomole AMC release), are shown.
Western blotting
Total proteins from cell lysates were separated by
SDS–polyacrylamide gel electrophoresis and electro-
blotted to nitrocellulose membranes. The membranes
were probed with the following primary antibodies: S-12
(murine anti-EBV LMP1 mAb); C4 (murine anti-human
actin mAb; Boehringer); C2–10 (murine anti-human PARP;
Pharmingen); 8E8 (murine anti-human A20 mAb; a kind
gift from Dr. Claudius Vincenz, Ann Arbor, MI); 124 (mu-
rine anti-human Bcl-2; DAKO); C20 (goat anti-human 55
kDa TNFR1 antibody; Santa Cruz Biotechnology). The
antibodies were diluted in 0.5% nonfat milk in Tris-buff-
ered saline (TBS). After washing with 0.1% Tween 20 in
TBS, the filter was incubated with horseradish peroxi-
dase (HPR)-linked anti-murine immunoglobulin (Ig), ex-
cept for the anti-TNFR1 immunoblotting in which a rabbit
anti-goat conjugated (DAKO) was used, and the film was
developed with enhanced chemiluminescence (ECL), ac-
cording to the manufacturer’s instructions (Amersham).
Flow cytometry
Flow cytometric analysis of the surface expression of
Fas was carried out as previously described (Fadeel et
al., 1997). Briefly, the monolayer cells were detached
from the flasks by trypsinization. Cells were pooled in
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complete medium, fixed with 1% paraformaldehyde, and
washed in sterile PBS prior to incubation with anti-Fas
mAb for 1 h at 4°C. Cells then were washed twice with
PBS and incubated with FITC-conjugated rabbit anti-
murine immunoglobulin (DAKO). Following incubation for
30 min at 37°C, cells were washed twice and resus-
pended in PBS. Indirect immunofluorescence was mea-
sured using a FACScan flow cytometer (Becton–Dickin-
son). Fluorescence data were processed using the
CellQuest software and are presented as logarithmic
histograms. Jurkat cells were employed as a positive
control.
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